3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
21
Triple Negative Breast Neoplasms
12
Inflammatory Breast Neoplasms
2
Carcinoma, Adenoid Cystic
2
Resectable HER2-positive Breast Cancer
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplastic Cells, Circulating
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Hodgkin Disease
1
HR+/HER2- Breast Cancer
1
Epstein-Barr Virus Infections
1
Down Syndrome
1
CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
1
Interventions
pembrolizumab
4
Cyclophosphamide
4
Radiotherapy
3
Cisplatin
3
fludarabine
2
Doxorubicin
2
Carboplatin
2
zimberelimab
1
olaparib
1
lenvatinib
1
envafolimab
1
avelumab
1
Thymectomy
1
Taxes
1
Sunitinib
1
Robotic Surgical Procedures
1
Ramucirumab
1
Radiotherapy, Adjuvant
1
Paclitaxel
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Etoposide
1
Drug Therapy
1
Chemoradiotherapy
1
Cetuximab
1
AP 1903 reagent
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Thymoma
×
Epirubicin
×
1 year
×
Clear all
No trials found.